Disclosure: SunnyPharma.info does not sell medication. This page is for informational purposes only and does not constitute medical advice. If you experience side effects from HIV treatment, contact your HIV care provider before making any changes to your regimen.
Dr. Jürgen Epple
Medical Reviewer
Karen Cooksey
Medical Writer
Modern antiretroviral therapy is exceptionally well tolerated compared to earlier HIV drug generations — but it is not side-effect-free. Understanding which side effects are common and transient, which are rare but serious, and which may emerge over years of treatment helps patients make informed decisions and know when to contact their care team. This page covers the full side-effect profile of HIV treatment in 2026, with particular focus on the INSTI-based regimens that are now standard first-line care for most people.
Side Effects by Phase of Treatment
The timing of side effects matters as much as their nature. Most patients on modern ART experience a predictable trajectory: some transient early symptoms that fade within weeks, then a long period of excellent tolerability, with a small number of slowly emerging long-term considerations requiring periodic monitoring.
The most common side effects of HIV treatment occur in the first weeks and are predominantly gastrointestinal. They reflect the body adjusting to the new medication and typically resolve on their own without requiring a regimen change.
- Nausea — the most frequently reported early symptom; usually mild to moderate; improved by taking medication with food (where not contraindicated)
- Diarrhoea or loose stools — common in the first 2–4 weeks; generally self-limiting
- Headache — reported in a minority of patients starting new ART; typically resolves within 2 weeks
- Fatigue — can occur on initiation; also partly reflects the immune system beginning to reconstitute
- Vivid dreams or sleep disturbance — particularly associated with older NNRTI-based regimens (efavirenz); less common with modern INSTIs
- Mild rash — usually self-limiting; only rarely indicates hypersensitivity
After the initial adjustment period, the vast majority of patients on modern INSTI-based regimens report no ongoing medication-related symptoms. The most notable development in the first year is weight gain, which typically begins in the first few months and continues gradually.
- Weight gain — begins in the first months; average 2–4 kg in year one on INSTI-based regimens; more pronounced in some patients
- Neuropsychiatric effects — insomnia, mood changes, and cognitive effects are rare with bictegravir and dolutegravir but have been reported; more common in patients with pre-existing mental health conditions
- Lipid changes — modest increases in total cholesterol and triglycerides; typically not clinically significant with modern regimens but warrant monitoring
- Creatinine elevation — bictegravir and dolutegravir inhibit tubular secretion of creatinine, causing a small apparent rise in serum creatinine that does not reflect true kidney function decline
Long-term considerations with modern ART are real but generally manageable. They rarely require treatment changes and are far less severe than the long-term effects seen with older drug generations. Routine monitoring at 6–12 month intervals is sufficient for most patients.
- Cumulative weight gain — continues gradually over years; on average 4 kg by 96 weeks across INSTI-based trials; clinically significant in a subset of patients
- Bone mineral density — modest decline in the first year of treatment (particularly with TDF-containing regimens), then stabilises; clinically significant fractures are rare with modern TAF-based regimens
- Renal function — real (not apparent) decline in kidney function is uncommon with TAF-based regimens; more associated with older TDF-based drugs; requires monitoring in patients with pre-existing kidney disease
- Cardiovascular risk — residual immune activation even on suppressive ART contributes to modestly elevated cardiovascular risk; management focuses on modifiable risk factors (smoking, blood pressure, lipids) rather than drug change
- Liver enzyme elevations — uncommon with modern regimens in patients without hepatitis co-infection; more relevant in patients with HIV/HBV or HIV/HCV co-infection
Side Effects by Drug Class
Different antiretroviral drug classes carry different side-effect profiles. Understanding which class is causing a symptom helps guide clinical decisions about regimen modification.
| Drug Class | Common Side Effects | Notable Rare/Serious Effects | Modern Status |
|---|---|---|---|
| INSTIs (bictegravir, dolutegravir) | Weight gain, mild GI symptoms, apparent creatinine rise, occasional insomnia | Rare neuropsychiatric effects (mood, anxiety, insomnia) — more common in patients with prior psychiatric history | Preferred — best tolerability profile |
| NRTIs — TAF (tenofovir alafenamide) | Weight gain (more than TDF), mild GI effects | Less kidney and bone toxicity than TDF; weight gain more pronounced | Preferred backbone agent |
| NRTIs — TDF (tenofovir DF) | GI symptoms, modest bone density reduction | Proximal renal tubulopathy (Fanconi syndrome) — rare; requires monitoring in patients with kidney disease | Used in PrEP; largely replaced by TAF in ART |
| NNRTIs (rilpivirine, efavirenz) | CNS effects (vivid dreams, dizziness, mood changes — mainly efavirenz); rash | Severe rash, hepatotoxicity (rare); efavirenz has significant CNS side-effect burden | Rilpivirine used in modern STRs; efavirenz largely phased out |
| Protease Inhibitors (boosted) | GI side effects (nausea, diarrhoea), lipid elevations, drug interactions via CYP3A4 | Lipodystrophy (older PIs); nephrolithiasis (atazanavir); significant drug interaction burden with cobicistat/ritonavir boosting | Second-line or in specific scenarios; not preferred first-line |
| Older NRTIs (stavudine, zidovudine, didanosine) | Significant mitochondrial toxicity, lipodystrophy, peripheral neuropathy, anaemia | Lactic acidosis (rare but potentially fatal); lipoatrophy; pancreatitis (ddI) | No longer recommended — legacy use only |
Serious Side Effects Requiring Immediate Attention
While serious adverse events are rare with modern ART, patients and their care teams should know the warning signs that require prompt medical evaluation.
Seek immediate medical attention if you experience:
• Severe rash, particularly with fever, blistering, or mucous membrane involvement — may indicate Stevens-Johnson syndrome or hypersensitivity reaction
• Severe abdominal pain, nausea and vomiting, or unusual fatigue with muscle weakness — possible lactic acidosis (rare with modern regimens but potentially life-threatening)
• Jaundice, dark urine, or significant right upper quadrant pain — signs of hepatotoxicity
• Severe chest pain, shortness of breath — cardiovascular events, which occur at higher rates in people with HIV than in HIV-negative peers
• New or worsening psychiatric symptoms — depression, suicidal ideation, severe anxiety — particularly in the first weeks of a new regimen
INSTI-Related Neuropsychiatric Effects
Neuropsychiatric side effects associated with integrase inhibitors — sleep disturbance, vivid dreams, mood changes, and anxiety — have been reported across the class. The incidence is higher with dolutegravir than with bictegravir in comparative analyses, and higher still with older INSTIs like elvitegravir or raltegravir in certain patient populations.
A 2019 meta-analysis found that dolutegravir was associated with a small but statistically significant increase in neuropsychiatric adverse events compared to comparator regimens. The absolute risk remains low, but patients with a pre-existing history of depression, anxiety, or other psychiatric conditions should be monitored more closely when starting an INSTI-based regimen and should be counselled on what symptoms to watch for.
Clinical note: A significant proportion of neuropsychiatric symptoms reported in the first weeks of starting ART reflect the psychological adjustment to an HIV diagnosis rather than drug toxicity. Distinguishing between drug-related effects and adjustment reactions requires clinical judgement and ideally a review at 4–6 weeks after initiation. If symptoms are severe or persistent, a switch to an alternative INSTI (e.g. from dolutegravir to bictegravir) or a different class is feasible with preserved virological outcomes in most patients.
Weight Gain: The Most Discussed Long-Term Side Effect
Weight gain on modern ART is the subject of considerable clinical attention and ongoing research. The phenomenon is well-documented across multiple large cohort studies and clinical trials, and reflects a combination of factors: the “return to health” effect as the body reconstitutes after chronic illness, a class effect of INSTIs on metabolic regulation, and possibly a role for TAF versus TDF in adipose tissue distribution.
Key evidence points:
- Average weight gain across INSTI-based regimen trials is approximately 2–4 kg in the first year and 4–6 kg by 96 weeks.
- Greater weight gain is observed in patients starting with lower CD4 counts (reflecting a larger return-to-health component) and in female patients and Black patients across most cohort datasets.
- Weight gain stabilises over time in most patients; it does not appear to be a linear continuing trend indefinitely.
- Clinically significant obesity (BMI >30) develops in a minority of patients — estimates range from 10–25% depending on the cohort and baseline BMI.
- Switching from TAF to TDF, or from an INSTI to a non-INSTI regimen, has been associated with modest weight reduction in some studies, but switching purely for weight management is not routinely recommended given the virological and tolerability trade-offs.
For a detailed review of the weight gain evidence specific to Biktarvy — including the 5-year trial data and what predicts who gains most — see the Biktarvy and weight gain page.
Modern ART vs Older Regimens: How Side Effects Have Changed
- 1 pill daily — low adherence burden
- GI side effects mostly transient and mild
- Minimal CNS effects (bictegravir)
- No lipodystrophy
- Minimal kidney toxicity (TAF vs TDF)
- Modest bone density effects
- Weight gain is the main ongoing concern
- <1% discontinuation due to side effects at 5 years
- Multiple pills, multiple times daily
- Significant GI intolerance common
- CNS effects frequent (efavirenz)
- Lipoatrophy and lipodystrophy
- Significant kidney toxicity (TDF, indinavir)
- Substantial bone density loss
- Peripheral neuropathy (d4T, ddI)
- High discontinuation rates due to toxicity
Managing Side Effects: Practical Guidance
Most side effects of modern ART can be managed without changing the regimen. The following approaches are used in clinical practice:
- GI side effects: Taking medication with a small amount of food can reduce nausea, even for drugs without a formal food requirement. Antacids containing calcium, magnesium, iron, or zinc should be separated from INSTI dosing by at least two hours due to drug interaction rather than GI concerns — see Biktarvy drug interactions for the full list.
- Insomnia or vivid dreams: Switching the dosing time from morning to evening (or vice versa) can help. For significant insomnia, a switch to bictegravir from dolutegravir may be considered given bictegravir’s lower neuropsychiatric signal.
- Weight gain: Dietary modification and physical activity remain the primary interventions; no pharmacological approach has been specifically validated for ART-associated weight gain. Regimen switching has modest evidence but is generally not first-line.
- Apparent creatinine rise: Requires no clinical action in most cases — the rise reflects inhibition of tubular creatinine secretion, not kidney damage. True GFR assessment (via cystatin C) can clarify if there is genuine concern.
For side-effect information specific to Biktarvy — the most widely used modern regimen — see the comprehensive Biktarvy side effects guide and the Biktarvy long-term side effects review. For the full drug interaction picture across antiretroviral classes, see what is antiretroviral therapy.
Frequently Asked Questions
The most common side effects of modern HIV treatment are gastrointestinal — nausea, diarrhoea, and stomach discomfort — and these occur mainly in the first two to four weeks after starting treatment, then resolve in the majority of patients. Weight gain is the most consistently reported longer-term side effect of INSTI-based regimens, with an average gain of around 4 kg by two years across major clinical trials. Headache and fatigue are also reported early but are usually transient. The discontinuation rate due to side effects with modern regimens like Biktarvy is under 1% at five years in clinical trial data.
Modern INSTI-based regimens have a substantially better long-term safety profile than earlier HIV drug generations. The long-term considerations with current preferred regimens — modest effects on weight, kidney function markers, and bone density — are real but rarely cause clinically significant harm with appropriate monitoring. They are far less severe than the lipodystrophy, significant kidney damage, and peripheral neuropathy associated with older antiretroviral drugs. The risk of not treating HIV — ongoing immune damage, AIDS-defining illness, and dramatically shortened life expectancy — vastly outweighs the side-effect risks of modern treatment for virtually all patients.
Neuropsychiatric side effects — including insomnia, vivid dreams, mood changes, anxiety, and depression — have been reported with integrase inhibitor-based regimens, particularly dolutegravir. The absolute incidence is low, but the risk is higher in patients with pre-existing psychiatric conditions. Bictegravir has a lower neuropsychiatric signal than dolutegravir in comparative data. Efavirenz, an older NNRTI no longer recommended as first-line, had significant CNS side effects including depression and vivid dreams that affected many patients. If neuropsychiatric symptoms emerge on a new regimen, they should be reported to the HIV care team — regimen modification is feasible if symptoms are significant.
Most side effects of modern HIV treatment that occur in the first weeks — nausea, diarrhoea, headache, fatigue — resolve within 2 to 4 weeks as the body adjusts to the medication. A minority of patients experience persistent GI symptoms beyond the first month. Neuropsychiatric side effects, if they occur, may also resolve over time or may persist, requiring clinical assessment. Long-term side effects such as weight gain develop gradually over months to years and do not resolve spontaneously without lifestyle intervention or, in some cases, regimen modification. The key principle is that the vast majority of patients reach a stable, symptom-free steady state after the initial adjustment period.
No — do not stop HIV medication without speaking to your HIV care provider first. Stopping ART abruptly causes viral rebound, which can rapidly undo immune recovery and restore transmission risk. It also creates conditions in which drug resistance can develop if treatment is restarted. If side effects are significant, contact your HIV care team — most side effect concerns can be addressed through dosing adjustments, supportive management, or, if necessary, a switch to a different regimen with preserved viral suppression. There are many effective ART options available, and tolerability issues rarely mean you are out of treatment options.
Yes — drug interactions are an important consideration with antiretroviral therapy. INSTI-based regimens like Biktarvy interact with antacids, supplements, and medications containing divalent cations (calcium, magnesium, iron, zinc), which must be separated from dosing by at least two hours. Protease inhibitor-based regimens boosted with cobicistat or ritonavir have very broad drug interaction profiles due to CYP3A4 inhibition, affecting many common medications including statins, steroids, and some antibiotics. Always inform all healthcare providers — including dentists and pharmacists — that you are on HIV treatment before starting any new medication. A comprehensive HIV drug interaction checker is available at hiv-druginteractions.org.
References
- Sax PE et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2017;4(11):e536-e546.
- Molina JM et al. Bictegravir, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection: five-year results from the GS-US-380-1490 study. Lancet HIV. 2022;9(5):e323-e332.
- Bourgi K et al. Greater Weight Gain in Treatment-Naive Persons Starting Dolutegravir-Based Antiretroviral Therapy. Clin Infect Dis. 2020;70(7):1267-1274.
- Menard A et al. Neuropsychiatric adverse effects of integrase strand transfer inhibitors. AIDS. 2019;33(7):1203-1211.
- Stellbrink HJ et al. Long-term bone mineral density and turnover changes in treatment-naive HIV-positive adults receiving tenofovir alafenamide-based regimens. J Infect Dis. 2020;222(1):83-91.
- DHHS Panel on Antiretroviral Guidelines. Adverse Effects of Antiretroviral Agents. In: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Updated January 2025. clinicalinfo.hiv.gov.
- University of Liverpool HIV Drug Interactions Database. hiv-druginteractions.org. Accessed March 2026.